CatalYm GmbH is a clinical-stage biotechnology company based in Planegg-Martinsried near Munich, Germany, developing next-generation cancer immunotherapies. Its lead approach neutralizes GDF-15 (Growth Differentiation Factor 15) to reverse a key immune-resistance mechanism in solid tumors, aiming to reinstate anti-tumor immune activity and… - View it on GitHub